

0300



KLAUBER & JACKSON
ATTORNEYS AT LAW
CONTINENTAL PLAZA
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

STEFAN KLAUBER*
DAVID A. JACKSON
STEVE S. CHA
VALETA A. GREGG, PH.D.*
STEPHEN GIGANTE
LAWRENCE D. MANDEL*
CATHERINE ROSEMAN SMITH*

PATENT, TRADEMARK
AND
COPYRIGHT CAUSES
(201) 487-5800
FACSIMILE: (201) 343-1684
WWW.KJIPLAW.COM
email: info@kjiplaw.com

*BAR OTHER THAN N.J.
* COUNSEL

PATENT AGENTS

CHRISTINE E. DIETZEL, PH.D.
MICHAEL A. YAMIN, PH.D.

SCIENTIFIC ADVISOR

VERONICA M. MALLON, PH.D.

May 21, 2002

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

RE: U.S. Patent Application
Inventors: Daniel Hawiger et al.
Title: ENHANCED ANTIGEN DELIVERY AND
MODULATION OF THE IMMUNE RESPONSE
THEREFROM
Serial No.: 09/925,284
Filed: August 9, 2001
Our File: 600-1-081CON/CIP

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box Sequence, PO Box 2327, Arlington, VA 22202 on May 21, 2002.

David A. Jackson, Reg. No. 26,742
(Name of Registered Representative)

Anna M. Jones 5/31/02
(Signature and Date)

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:


Responsive to the Notice dated March 25, 2002, with a due date of May 25, 2002, indicating that the previously forwarded Sequence Listing Disk was damaged, and in accordance with 37 CFR 1.821 - 1.825, Applicants submit herewith the following:

1. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.
2. A copy of the Sequence Listing in computer readable form.
3. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.

Applicants request favorable consideration and entry of the Sequence Listing submitted herewith and further and favorable processing of the present Application.

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'DAVID A. JACKSON', is written over a horizontal line.

DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

DAJ:aj
Enclosures



PATENT

600-1-081 CON/CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Daniel Hawiger et al.

EXAMINER : Unassigned

SERIAL NO.: 09/925,284

ART UNIT: 1645

FILED : August 9, 2001

FOR: ENHANCED ANTIGEN DELIVERY AND MODULATION
OF THE IMMUNE RESPONSE THEREFROM**CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, PO Box 2327, Arlington, VA 22202 on May 21, 2002.

David A. Jackson, Reg. No. 26,742
(Name of Registered Rep.)

David A. Jackson 5/21/02.
(Signature and Date)

**STATEMENT IN SUPPORT OF THE FILING/SUBMISSION OF A
NUCLEOTIDE/AMINO ACID SEQUENCE LISTING IN
ACCORDANCE WITH 37 CFR §1.821-1.825**

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202


Dear Sir:

DAVID A. JACKSON, attorney of record, hereby states as follows:

1. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 CFR §1.821 (c) and (e), respectively, are the same.

2. I hereby state that the submission, filed in accordance with 37 CFR §1.821 (g) herein does not contain new matter.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicant
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800
Dated: May 21, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/925,284	08/09/2001	Daniel Hawiger	600-1-081 CON/CIP

23565
KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NJ 07601

CONFIRMATION NO. 2660

FORMALITIES LETTER



OC000000007708328

Date Mailed: 03/25/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Malvika Bopale

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE